Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Ian Ratheal

Orthopaedic Surgery New Braunfels, TX Medical Doctor

NPI 1639558810 CMS profile 1341462

960 Gruene Rd Ste 101, New Braunfels, TX 78130

Open in the dashboard

General payments

$7,376

70 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Ian Ratheal of New Braunfels, TX is reported in the CMS Open Payments database as having received $7,376 across 70 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $94 2
2023 General $196 3
2022 General $3,834 26
2021 General $1,310 20
2019 General $1,942 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ian Ratheal
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Ian Ratheal were reported at $0. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Ian Ratheal Orthopaedic Surgery median Middle half National median
2019 $1,942 $644 $140–$2,844 $163
2020 $0 $312 $75–$1,860 $114
2021 $1,310 $520 $117–$2,495 $132
2022 $3,834 $598 $128–$2,731 $149
2023 $196 $461 $128–$2,264 $160
2024 $94 $497 $134–$2,475 $164
2025 $0 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Encore Medical, LP $3,267 24 payments
  2. Stryker Corporation $2,065 13 payments
  3. Orthalign Inc $879 9 payments
  4. Bioventus LLC $260 8 payments
  5. DePuy Synthes Sales Inc. $239 5 payments
  6. Davol Inc. $142 1 payment
  7. Regeneron Healthcare Solutions, Inc. $131 1 payment
  8. Ortho Development Corporation $107 1 payment
  9. SPR Therapeutics, Inc $78 1 payment
  10. Corium, Inc. $71 1 payment
  11. Other $138 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,688 61 payments
  2. Travel and Lodging $2,188 8 payments
  3. Honoraria $1,500 1 payment
Products named General payments · program years 2019–2024
  1. DJO SURGICAL Joint Implants $2,945 16 payments
  2. DJO SURGICAL Joint Implants $1,637 3 payments
  3. T2 $1,279 1 payment
  4. VARIAX $1,279 1 payment
  5. AXSOS $1,279 1 payment
  6. HOFFMANN $1,279 1 payment
  7. GAMMA $1,279 1 payment
  8. ORTHALIGN PLUS $879 9 payments
  9. MAKO $392 3 payments
  10. TRAUMA $294 8 payments
  11. Other $1,821 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

205

Median for Orthopedic Surgery: 203

Drug cost

$4,711

Median for Orthopedic Surgery: $1,433

Branded share of claims

22.9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 12 $3,542
Gabapentin Generic 40 $278
Oxycodone Hcl Generic 22 $250
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 24 $209
Celecoxib Generic 11 $151
Acetaminophen-Codeine Acetaminophen With Codeine Brand 11 $99
Meloxicam Generic 60 $93
Tramadol Hcl Generic 25 $90

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$8,245

Of which drugs: $77

Medicare patients

33

Average age 75

Services billed

152

15 women, 18 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 52%
Diabetes 33%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 96 $77

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

70 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record